Neurologic status\r\n* Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to enrollment\r\n* Patients with seizure disorders may be enrolled if seizures are well controlled on an anti-epileptic drug that is not a strong inducer or inhibitor of CYP3A4/5 are eligible
Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to registration
Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to registration
Patients with neurological deficits should have deficits that are completely stable for a minimum of 1 week (7 days) prior to enrollment
INCLUSION CRITERIA FOR STRATUM C: Patients with neurological deficits should have deficits that are completely stable for a minimum of 1 week (7 days) prior to enrollment
Patients with neurological deficits that are stable for a minimum of one week prior to registration
Any neurologic deficits must be stable for >= 1 week
Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to registration
Patients with neurological deficits should have deficits that are stable for a minimum of 2 weeks prior to registration
Cerebrovascular accident (CVA) with persistent neurologic deficits occurring within 6 months prior to enrollment; persisting neurologic deficits from a CVA occurring over 6 months prior to enrollment are not necessarily grounds for exclusion
Stable neurologic deficits on a stable dose of corticosteroids (if applicable) for at least 1 week before study enrollment
At the time of study enrollment patients must have a life expectancy of greater than or equal to 2 months; neurologic deficits in patients with CNS tumors must have been relatively stable for a minimum of 1 week prior to study enrollment
Neurologic deficits must have been relatively stable for a minimum of 1 week prior to study enrollment
Patients with neurological deficits should be stable for a minimum of 1 week prior to enrollment
Patients with neurological deficits should have deficits that are stable or improving for a minimum of 1 week prior to registration
Neurologic status\r\n* Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to enrollment\r\n* Patients with seizure disorders may be enrolled if seizures are well controlled
Any active neurologic and/or psychiatric disease, history of significant head trauma followed by persistent neurologic deficits, or known structural brain abnormalities
Patient with multiple, serious major neurologic deficits including encephalopathy.
Any neurologic deficits must be stable for >= 1 week
Neurologic deficits that are rapidly progressing: all neurologic signs and symptoms must have been stable for a week prior to first dose
Neurological deficits must be stable on a fixed or decreasing dose of dexamethasone for >= 7 days before study enrollment
Any neurologic deficits must be stable for >= 1 week
Neurologic deficits that are rapidly progressing; all neurologic signs and symptoms must have been stable for a week prior to first dose
DONOR: Severe neurologic deficits
Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to registration; this is to be documented at baseline
Neurologic deficits: Patients with central nervous system (CNS) tumors must have stable neurological deficits for a minimum of 1 week prior to study entry
For patients with CNS tumors (primary or metastatic), any baseline neurologic deficits (including seizure) must be stable for at least one week prior to study enrollment
No orthopedic restrictions or neurologic deficits that would limit ability to complete the Power Protocol (based on the opinion of the investigator)
